Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Open Access
- 1 October 2013
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 340 (1), 97-103
- https://doi.org/10.1016/j.canlet.2013.07.007
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Emerging role of multikinase inhibitors for refractory thyroid cancerBiologics: Targets and Therapy, 2012
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyondDrug Design, Development and Therapy, 2011
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung CancerCell, 2007
- RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize LectureActa Endocrinologica, 2006
- BAY 43-9006 Inhibition of Oncogenic RET MutantsJNCI Journal of the National Cancer Institute, 2006
- cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell lineBiochemical and Biophysical Research Communications, 1990